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Abstract 
Background: In August 2011, the Specialized Center for Diabetes and Pregnancy of the Botucatu Medical School/
Unesp adopted a new diagnostic protocol for gestational diabetes mellitus, recommended by the American Diabe-
tes Association and the International Association of the Diabetes and Pregnancy Study Group. The glycemic profile 
was evaluated using the 75-g oral glucose tolerance test (OGTT) used to diagnose mild gestational hyperglycemia, 
recognized and treated in our department as gestational diabetes mellitus. The cost-effectiveness of the new guide-
lines and the continued need for the evaluation of the glycemic profile, as part of our Service protocol, are controver-
sial and require further investigation. We aimed to assess the impact of the new guidelines on the evaluation of mild 
gestational hyperglycemia and gestational diabetes mellitus, the incidence of adverse perinatal outcomes, and the 
association between the 75-g OGTT and the glycemic profile for the diagnosis of mild gestational hyperglycemia.
Methods: This cross-sectional study was performed identifying a convenience sample of pregnant women and their 
newborns. The women used our Service for diagnostic procedures, prenatal care and delivery, both before (January 
2008 to August 14, 2011) and after (August 15, 2011 to December 2014) the protocol modification. The following 
variables were compared, following stratification according to diagnostic protocol: prevalence of gestational diabetes 
mellitus and mild gestational hyperglycemia, newborns large for gestational age, macrosomia, first cesarean delivery, 
and newborn hospital stay. Statistical analysis was performed using Poisson regression, the Student’s t test, the Chi 
square or Fisher’s exact test and risk estimate. The statistical significance threshold was set at 95% (p < 0.05).
Results: The new protocol resulted in an 85% increase in the number of women with GDM, but failed to identify 
17.3% of pregnant women classified as having mild gestational hyperglycemia, despite a normal 75-g OGTT. The new 
guidelines did not affect perinatal outcome.
Conclusions: These results support the validity of maintaining the glycemic profile as part of the diagnostic protocol 
at our hospital. Large multicenter studies with an adequate sample size are required for conclusive evidence on the 
cost-effectiveness of the new protocol.
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Background
Gestational diabetes mellitus (GDM) is defined as any 
degree of glucose intolerance developing or first detected 
during pregnancy [1, 2]. Recently, the American Diabetes 
Association (ADA) re-defined GDM as follows: “diabe-
tes diagnosed in the second and third trimesters of preg-
nancy” [3].
Irrespective of the definition of glucose intolerance and 
diabetes and regardless of the pregnancy period, this con-
dition of hyperglycemia, if untreated, can lead to adverse 
perinatal outcomes (APNO). The most frequent adverse 
events include the increased risk of birth trauma and 
the higher incidence of cesarean sections, macrosomia, 
episodes of neonatal hypoglycemia, and respiratory dis-
tress syndrome and/or prematurity, all of which increase 
the risk of perinatal death [4]. Children of mothers with 
GDM have a higher risk of developing obesity and meta-
bolic syndrome (MS), which have repercussions in adult-
hood [4–6]. Mothers with GDM are also at an increased 
risk of developing type 2 diabetes mellitus (DM2) and MS 
in later life, as well as preeclampsia in subsequent preg-
nancies [7, 8].
The importance of maternal hyperglycemia, regard-
less of the diagnostic criteria for GDM, was first high-
lighted by Rudge and colleagues in 1990. The authors 
combined the 100-g oral glucose tolerance test (OGTT) 
with the glucose profile (GP) for the diagnosis of GDM. 
Four groups were identified on the basis of the response 
to these two tests: IA, IB, IIA, and IIB. In group IA, both 
the OGTT and GP were normal; in group IB, the OGTT 
was normal and the GP was changed; in group IIA, the 
OGTT was changed and GP was normal; and in group 
IIB, both test results were changed [9].
GP consisted of daytime assessments (8–6  p.m.) of 
maternal plasma glucose every 2 h, with a 2840 kcal diet, 
divided into five meals: breakfast, lunch, dinner, and two 
daytime snacks. Fasting glucose levels of 90  mg/dL and 
postprandial levels of 130 mg/dL were set as the normal 
reference values. Values greater than or equal to the ref-
erence values identified a changed test result, and hyper-
glycemia was confirmed, regardless of the outcome of the 
100-g OGTT [9].
This classification and the treatment protocol are cur-
rently used in the Specialized Center for Diabetes and 
Pregnancy of the Clinical Hospital of Botucatu Medical 
School/Unesp (SEDG-FMB/Unesp). Pregnant women in 
group IA are followed-up in the low risk prenatal group; 
those in group IB with mild gestational hyperglycemia 
(MGH) are treated as having GDM. The pregnant women 
in groups IIA and IIB have GDM and receive individu-
alized treatment, which includes exercise and dietary 
advice, encouragement for physical activity, and the 
administration of insulin, if required [9, 10].
The following findings were also observed the study by 
Rudge et al. Firstly, there was a comparable rate of new-
borns (NB) large for gestational age (LGA) born to moth-
ers in groups IB, IIA and IIB. Secondly, the incidence of 
type 2 diabetes (DM2) in groups IB and IIA, 8–12 years 
after the index pregnancy, was equivalent. Thirdly, peri-
natal mortality in group IB was 10 times greater than 
that in group IA and comparable to that observed in the 
group of mothers with GDM. Furthermore, the study also 
identified approximately 20% of pregnant women with 
altered diagnostic test results requiring treatment for 
the control of hyperglycemia [10]. These findings high-
light the importance of tracking, diagnosing and treating 
MGH in the same manner as GDM.
In 2011, the American Diabetes Association (ADA) 
recommended comprehensive changes to the diagnostic 
criteria for GDM [1]. A new protocol was developed by 
the International Association of Diabetes and Pregnancy 
Study Group (IADPSG) [11] on the basis of the results 
of the Hyperglycemia and Adverse Pregnancy Outcome 
(HAPO) Study [12]. This study included 23,316 women 
undergoing the 75-g OGTT between 24 and 32 weeks of 
pregnancy. It showed a directly proportional correlation 
between maternal blood glucose levels and the occur-
rence of predefined primary outcomes: birth weight 
above the 90th percentile (P90), need for a first cesar-
ean section, neonatal hypoglycemia, and high levels of 
C-peptide in the umbilical cord [12].
The ADA/IADPSG diagnostic protocol [1] recom-
mends the following: (1) investigation during the first 
trimester of pregnancy to identify women with overt, 
undiagnosed DM, by testing fasting glucose (≥126  mg/
dL), glycated hemoglobin (HbA1c) (≥6.5%) or ran-
dom blood glucose (≥200  mg/dL). A single confirmed 
changed test result is sufficient for the diagnosis of overt 
diabetes; (2) universal screening of all pregnant women, 
with no pre-existing diagnosis of overt diabetes, between 
24 and 28 weeks of pregnancy. Screening consists of the 
75-g OGTT and the collection of three glucose samples 
(fasting, 1 and 2  h after the glucose overload, respec-
tively) where the normal limits are, respectively, 92, 180, 
and 153  mg/dL. One changed value is sufficient for the 
diagnosis of GDM [11]. This protocol was recommended 
by the ADA in January 2011 and implemented within 
our department (as a Service diagnostic protocol) from 
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August 15, 2011. However, GP was maintained, irrespec-
tive of the outcome of the 75-g OGTT.
Several studies have assessed the impact of these new 
criteria on the prevalence of GDM and perinatal out-
comes as well as have determined the cost-effectiveness. 
So far, results suggest an increased prevalence of GDM, 
with values ranging from 10 to 25%, and minimal effect 
on perinatal outcomes; however, there are significant 
inconsistencies. Further research is required to assess 
the cost-effectiveness of these new recommendations 
[13–17].
Following a critical review, the World Health Organi-
zation (WHO) also proposed changes to the diagnos-
tic protocol of maternal hyperglycemia, differentiating 
diabetes mellitus in pregnancy (DM during pregnancy) 
from GDM. According to the revised WHO guidelines, 
irrespective of gestational age, the diagnosis of DM 
during pregnancy is made on the basis of fasting glu-
cose ≥126 mg/dL; glucose ≥200 mg/dL, measured 2 h 
after a 75-g glucose load; or a random blood glucose 
level ≥200  mg/dL, associated with clinical symptoms. 
Fasting glucose values of 92–125 mg/dL or glucose lev-
els of 153–199  mg/dL, measured 2  h after a 75-g glu-
cose load, were used to confirm the diagnosis of GDM 
[18].
Further research is necessary to develop a single pro-
tocol, which is preferable. The combination of two diag-
nostic tests (OGTT and GP), as proposed by Rudge et al. 
[9], identifies approximately 20% of pregnant women 
with altered test results requiring treatment to control 
hyperglycemia [10]. This is comparable to the prevalence 
of GDM identified under the new ADA/IADPSG diag-
nostic criteria [11]. This conclusion raises doubts about 
the necessity of maintaining the GP as part of the Service 
diagnostic protocol because, with the reduced and more 
comprehensive limits of the 75-g OGTT, patients with 
MGH could now meet the diagnostic criteria of GDM.
The validity of the changes proposed by the new ADA/
IADPSG protocol is controversial [1, 11], yet the new 
protocol is already established as part of the Service since 
August 2011. In this context, the proposal for the pre-
sent study is justified. It is anticipated that the research 
will identify changes in the prevalence of GDM, define 
the role of GP in the MGH diagnostic protocol, evaluate 
the occurrence of APNO in pregnancies complicated by 
hyperglycemia or diabetes and, above all, contribute to 
improvements in the quality of the Service provided by 
our unit.
The aim of this study was to evaluate the impact of the 
new ADA/IADPSG protocol [1] on the prevalence of 
MGH and GDM, on the occurrence of APNO, and on the 
combination of the 75-g OGTT and GP for the diagnosis 
of MGH in SEDG-FMB/Unesp.
Methods
Design and study site
This cross-sectional cohort study was performed ana-
lyzing data stored in the SEDG/FMB-Unesp database. A 
convenience sample was defined; this included pregnant 
women who underwent diagnostic tests, prenatal care, 
and delivery, as part of the Service, before (January 2008 
to August 14, 2011) and after (August 15, 2011 to Decem-
ber 2014) the revisions to the GDM diagnostic protocol. 
The women’s newborns were also included in the study.
Study groups
Before the adoption of the new criteria, the Service diag-
nostic protocol included the 100-g OGTT, as set out by 
the 2010 ADA guidelines [19], combined with the GP [9, 
10]. Following the publication of the 2011 ADA guide-
lines for GDM, the Service adopted a new diagnostic pro-
tocol, replacing the 100-g OGTT with the 75-g OGTT, 
while maintaining the combined approach with the gly-
cemic profile [9, 10].
Therefore, both before and after the introduction of the 
new criteria, and despite the changes in the glucose load 
administered as part of the OGTT, the Service has always 
recognized Rudge’s classification: IA (normal OGTT 
and GP), IB (normal OGTT and changed GP—MGH), 
IIA (changed OGTT and normal GP—GDM), and IIB 
(changed OGTT and GP (GDM) [9]). For the purposes 
of this study, no distinction was made between Rudge’s 
groups IIA and IIB. Therefore, only three groups of preg-
nant women were identified:
  • Nondiabetic (ND—control).
  • Mild gestational hyperglycemia (MGH—normal 
OGTT and changed GP).
  • Gestational diabetes mellitus (GDM).
We compared the prevalence and perinatal outcomes 
of these groups, in predefined periods before and after 
the implementation of protocol changes (August 15, 
2011).
Perinatal outcomes
NB-LGA, defined as weight for gestational age ≥P90 [10]: 
number (n) and percentage (%);
  • Macrosomia, defined as birth weight  ≥4000  g [10]: 
number (n) and percentage (%);
  • First C-section, as an indirect marker of fetal mac-
rosomia [12]: number (n) and percentage (%);
  • Length of hospital stay, as an indirect marker of NB 
morbidity [10], defined by the time between birth 
and discharge of the NB, categorized as up to 3 days, 
4–7 days, and over 7 days.
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Treatment protocol
All pregnant patients diagnosed with MGH and GDM 
underwent the same treatment under the Service pro-
tocol both before and after the introduction of protocol 
changes [10]. This protocol includes guidance on ade-
quate nutrition from nutritionists, encouragement to 
exercise regularly and, whenever necessary, insulin asso-
ciated with dietary advice and exercise [20]. The control 
of maternal hyperglycemia was assessed by the glycemic 
profile at least every 15  days. When the average glyce-
mia was ≥120 mg/dL (calculated as the arithmetic mean 
of all blood glucose levels, measured as part of the GP), 
NPH insulin was administered with doses and applica-
tion times adjusted according to the glucose values and 
hyperglycemic peaks observed [10].
Statistical analysis
The relevant data were extracted from the database of the 
Service and saved in Excel 2010 spreadsheets. Data were 
checked for consistency of information.
We identified the relevant time periods for analysis, the 
diagnostic protocols (defined as “OLD” and “NEW”) and 
the resulting diagnoses, and the APNO. The mean values 
and their respective standard deviations were compared 
using Poisson regression and the Student’s t test. The Chi 
square or Fisher’s exact test were used to evaluate the 
associations between variables. We calculated the rela-
tive risk (RR) and the 95% confidence interval for APNO 
according to diagnostic protocols. A p value of <0.05 was 
considered statistically significant.
Results
There were no significant differences in the ND, MGH, or 
GDM groups with stratification of the subjects according 
to the OLD and NEW protocols. The only exception was 
the average number of previous cesareans in the GDM 
group, which was lower in women under the NEW pro-
tocol (p = 0.0370) (Table 1). The blood glucose levels at 
1 and 2 h post-glucose load were lower under the NEW 
protocol across groups (ND, MGH and GDM). Fast-
ing glucose was lower in MGH pregnant women under 
the NEW protocol than under the OLD protocol. GDM 
maintained during pregnancy was lower in the group of 
GDM pregnant women under the NEW protocol. The 
HbA1c level at the end of pregnancy was lower in ND 
pregnant women identified by the NEW protocol while 
no significant differences were observed in the MGH and 
GDM groups regardless of the diagnostic protocol used 
(Table 2).
The NEW protocol did not influence the prevalence 
of pregnant women in the ND, MGH, or GDM groups. 
Nevertheless, 17.3% of the pregnant women under this 
protocol were diagnosed with MGH and did not satisfy 
the new diagnostic criteria for GDM (Table  3) (with-
drawal statement).
There were no differences in the prevalence of APNO 
or in the corresponding relative risk analysis according to 
the diagnostic protocols tested (Tables 4, 5).
Discussion
In this study, the comparison between the OLD and the 
NEW GDM diagnostic protocol introduced by the ADA/
IADPSG did not reveal any statistically significant dif-
ferences in the prevalence of GDM and MGH or in the 
occurrence of APNO at SEDG-FMB/Unesp. The ADA/
IADPSG protocol did identify more women with GDM, 
however, it did not diagnose all cases of MGH as GDM. 
Of the 289 pregnant women treated under the NEW pro-
tocol, 17.3% still maintained the diagnosis of MGH, with 
normal 75-g OGTT and changed GP.
No statistically significant difference was found in 
APNO, irrespective of the diagnostic protocol. This find-
ing could be interpreted as negative in relation to the 
NEW ADA/IADPSG protocol. In this study, a sample 
of 194 newborns from mothers with GDM, obtained by 
convenience, may have been insufficient to demonstrate 
Table 1 Population characteristics in the ND, MGH and GDM groups stratified according to diagnostic protocol
Results expressed as mean ± SD
Poisson regression for the number of pregnancies and previous C-section
Student’s t test for the other analyses
ND non diabetic, MGH mild gestational hyperglycemia, GDM gestational diabetes mellitus, WG weight gain
ND (N = 199) MGH (N = 89) GDM (N = 194)
OLD NEW p OLD NEW p OLD NEW p
Pregnancies 2.59 ± 1.54 2.27 ± 1.54 0.1672 3.27 ± 2.05 3.14 ± 1.90 0.7368 3.30 ± 1.56 3.15 ± 1.58 0.5850
Previous C-sections 0.46 ± 0.77 0.40 ± 0.74 0.5094 1.03 ± 1.14 0.62 ± 0.83 0.0370 0.83 ± 0.87 0.64 ± 0.71 0.1596
Initial BMI (kg/m2) 28.83 ± 7.79 26.75 ± 5.85 0.1450 32.86 ± 4.29 30.38 ± 8.47 0.3976 31.13 ± 4.84 32.50 ± 7.28 0.4379
Final BMI (kg/m2) 33.40 ± 8.25 31.62 ± 5.27 0.3296 37.37 ± 4.89 34.36 ± 7.99 0.2579 35.01 ± 4.24 36.50 ± 6.30 0.3336
WG (kg) 15.11 ± 10.90 12.16 ± 6.80 0.1736 12.10 ± 6.65 10.52 ± 5.60 0.4356 10.69 ± 8.32 9.87 ± 7.84 0.6444
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statistically significant results in terms of the occurrence 
of NB-LGA, macrosomia, first C-section, and longer 
hospital stays of newborns. A recent Australian study 
showed beneficial effect of the ADA/IADPSG diagnostic 
protocol in the occurrence of macrosomia by reduc-
ing the risk of developing macrosomia, evaluating 559 
pregnant women and newborns [21]. Overall, our results 
are consistent with the available evidence and show an 
increase in the prevalence of GDM, ranging from 10 to 
25%, and little impact on perinatal outcomes. Further 
studies are required to define the cost-benefit ratio of 
these new recommendations [13–17].
Previous results from our research group, show that 
the cost-effective ratio of maternal and neonatal diag-
nosis and treatment for prior DM, GDM and MGH is 
always positive, with social profitability ratio ranging 
from 1.87 to 5.35 [22]. The treatment protocol was the 
same for both periods and the 75-g OGTT evaluates two, 
rather than three, post glucose load plasma glucose lev-
els. Therefore, identifying and treating more women with 
GDM should not change the cost-benefit indications and 
the NEW ADA/IADPSG protocol shall be followed at 
SEDG-FMB/Unesp.
Table 2 Results of the diagnostic tests and maternal glycemic control in the ND, MGH, and GDM groups stratified accord-
ing to diagnostic protocol
Results expressed as mean ± SD
Student’s t test for all analyzes
GA Glycemic average maintained during pregnancy, HbA1c glycated hemoglobin, ND non diabetic, MGH mild gestational hyperglycemia, GDM gestational diabetes 
mellitus
ND (N = 199) MGH (N = 89) GDM (N = 194)
OLD NEW p OLD NEW p OLD NEW p
GTT- fasting (mg/dL) 74.17 ± 7.22 72.54 ± 6.39 0.0979 84.13 ± 9.24 79.06 ± 7.97 0.0071 97.46 ± 21.74 93.41 ± 11.53 0.1937
GTT-1 h (mg/dL) 124.90 ± 29.91 109.00 ± 25.06 <0.0001 144.40 ± 23.45 135.30 ± 25.15 0.0864 197.40 ± 38.60 174.10 ± 33.70 0.0001
GTT-2 h (mg/dL) 102.70 ± 23.76 90.92 ± 19.60 0.0002 128.80 ± 24.42 114.90 ± 21.42 0.0057 191.40 ± 47.06 148.8- ± 33.54 <0.0001
GTT-3 h (mg/dL) 92.66 ± 20.79 – – 110.53 ± 24.88 – – 145.00 ± 41.97 –
GA (mg/dL) 83.35 ± 10.29 82.14 ± 7.40 0.3397 97.16 ± 7.49 95.31 ± 6.14 0.2056 106.30 ± 10.28 99.95 ± 8.83 <0.0001
HbA1c/delivery (%) 5.43 ± 0.40 5.17 ± 0.45 0.0055 5.57 ± 0.53 5.43 ± 0.54 0.3855 5.81 ± 0.71 5.64 ± 0.63 0.2516
Table 3 Prevalence of  pregnant women in  the ND, MGH, 
and GDM groups stratified according to diagnostic proto-
col
Results expressed in number (N) and percentage (%)
Test for the comparison of proportions (Chi square)




ND 86 (44, 6) 113 (39, 1) 0.2720
MGH 39 (2, 20) 50 (3, 17) 0.4928
GDM 68 (35, 2) 126 (43, 6) 0.0818
Total 193 289 482
Table 4 Perinatal outcomes in the ND, mild gestational hyperglycemia (MGH), and gestational diabetes mellitus (GDM) 
groups stratified according to diagnostic protocol
Results expressed in number (N) and percentage (%)
Test for the comparison of proportions
NB-LGA newborn large for the gestational age
ND (N = 199) MGH (N = 89) GDM (N = 194)
OLD NEW p OLD NEW p OLD NEW p
NB-LGA 0 (0, 0) 9 (8, 0) 0.0196 6 (4, 15) 7 (14, 0) 1.0000 6 (8) 14 (1, 11) 0.8006
Macrossomia 3 (4, 4) 5 (4, 4) 1.0000 6 (4, 15) 7 (14, 0) 1.0000 5 (3, 7) 13 (3, 10) 0.6747
First C-section 25 (25, 5) 43 (38, 1) 0.2409 8 (5, 20) 16 (32, 0) 0.3316 16 (5, 23) 30 (8, 23) 1.0000
Length of hospital stay (days)
1–3 64 (76, 6) 87 (77, 0) 0.8003 29 (74,4) 41 (82, 0) 0.5404 50 (73,5) 96 (76,2) 0.8138
4–7 14 (1, 11) 22 (5, 19) 0.6942 10 (25,6) 8 (16, 0) 0.3911 14 (6, 20) 25 (8, 19) 1.0000
>7 8 (2, 12) 4 (3, 5) 0.1642 0 (0, 0) 1 (2, 0) 1.0000 4 (5, 9) 5 (4, 0) 0.8049
Total 86 113 39 50 68 126
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Regarding the association of the GP to the 75-g OGTT 
for the diagnosis of MGH, it is clear that the new lim-
its and criteria recommended by the ADA/IADPSG 
also failed to identify 17% of women with MGH, which 
must be treated to prevent APNO [10]. In this study, all 
patients with MGH received the same standard treat-
ment as those with GDM and reached average glucose 
levels and HbA1c within the recommended limits for 
these pregnancies [20]. This study found 14–15% of NB-
LGA and macrosomia, 20–30% of need for a first C-sec-
tion, and about 10% of newborns with discharge after 
the third day of life. These pregnant women were already 
obese in the pre-pregnancy period and despite exhibiting 
lower levels of fasting glucose and of glucose 2 h after the 
75-g OGTT, 17 in 100 evaluated women showed hyper-
glycemic peaks in GP in response to a normocaloric daily 
diet [23]. These data support the combined use of the 
GP and the 75-g OGTT for the diagnosis of GDM and 
MGH. Indirectly, these results highlight the preventive 
role of pre-pregnancy obesity control and its metabolic 
effects in reducing insulin resistance and hyperglycemic 
disorders in pregnancy, which have a long-term impact 
on health [7, 8, 10].
This study has some limitations: (1) the study popu-
lation was a convenience sample, limited to pregnant 
women who underwent diagnosis tests, prenatal care 
and delivery at SEDG-FMB/Unesp, to ensure access 
to all data of interest; (2) the study was a cohort study 
that has limited applicability for analysis of the associa-
tion between the diagnostic protocols and perinatal out-
comes, (ideally, the protocols would be applied to the 
same pregnant women, over the same period) and (3) 
the characteristics of the service itself that, despite being 
a reference for pregnancies complicated by diabetes, has 
restricted demand. Nevertheless, our results highlight 
the validity of the review of each service, enable assess-
ment of local protocols and contribute to the broader dis-
cussion and critique of these yet undefined issues.
Conclusions
The comparison between the OLD and NEW GDM diag-
nostic protocols showed no statistically significant dif-
ference in the prevalence of GDM and MGH or in the 
occurrence of APNO, at SEDG-FMB/Unesp. However, in 
absolute numbers, the ADA/IADPSG protocol increased 
the number of cases diagnosed as GDM by 85.0%, and 
failed to identify all pregnant women with MGH; the 
changed GP identified 17.3% of pregnant women living 
with MGH, despite a normal 75-g OGTT. The results of 
this study indicate the validity of maintaining GP in the 
diagnostic protocol of SEDG-FMB/Unesp. Multicenter 
studies of larger samples should complete the cost-effec-
tiveness of the new GDM diagnostic protocol in prevent-
ing APNO.
The use of GP in clinical practice is absolutely feasible 
because it is an easily performed exam. A negative point 
could be the adherence of the patients to the examina-
tion due to the time of the examination, but in our prac-
tice, we observed that patients were once adhered to the 
screening.
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